期刊文献+

Current status and prospects of clinical proteomics studies on detection of colorectal cancer:Hopes and fears 被引量:3

Current status and prospects of clinical proteomics studies on detection of colorectal cancer:Hopes and fears
下载PDF
导出
摘要 Colorectal adenocarcinoma (CRC) is the third most common type of cancer and the fourth most frequent cause of death due to cancer worldwide. Given the natural history of CRC, early diagnosis appears to be the most appropriate tool to reduce disease-related mortality. A field of recent interest is clinical proteomics, which was reported to lead to high sensitivity and specificities for early detection of several solid tumors. This emerging field uses mass spectrometry-based protein profiles/patterns of easy accessible body fluids to distinguish cancer from non-cancer patients. These discrepancies may be a result of: (i) proteins being abnormally produced or shed and added to the serum proteome, (2) proteins clipped or modified as a consequence of the disease process, or (3) proteins subtracted from the proteome owing to disease-related proteolytic degradation pathways. Therefore, protein pattern diagnostics would provide easy and reliable tools for detection of cancer. This paper focuses on the current status of clinical proteomics research in oncology and in colorectal cancer especially, and will reflect on pitfalls and fears in this relatively new area of clinical medicine, which are reproducibility issues and pre-analytical factors, statistical issues, and identification and nature of discriminating proteins/peptides. Colorectal adenocarcinoma (CRC) is the third most com-mon type of cancer and the fourth most frequent cause of death due to cancer worldwide. Given the natural history of CRC, early diagnosis appears to be the most appropriate tool to reduce disease-related mortality. A fi eld of recent interest is clinical proteomics, which was reported to lead to high sensitivity and specifi cities for early detection of several solid tumors. This emerging fi eld uses mass spectrometry-based protein profi les/pat-terns of easy accessible body fluids to distinguish cancer from non-cancer patients. These discrepancies may be a result of: (1) proteins being abnormally produced or shed and added to the serum proteome, (2) proteins clipped or modified as a consequence of the disease process, or (3) proteins subtracted from the proteome owing to disease-related proteolytic degradation path-ways. Therefore, protein pattern diagnostics would pro-vide easy and reliable tools for detection of cancer. This paper focuses on the current status of clinical proteomics research in oncology and in colorectal cancer especially, and will re? ect on pitfalls and fears in this relatively new area of clinical medicine, which are reproducibility issues and pre-analytical factors, statistical issues, and identifi -cation and nature of discriminating proteins/peptides.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第41期6594-6601,共8页 世界胃肠病学杂志(英文版)
关键词 PROTEOMICS Colorectal cancer Protein profiling Diagnosis Biomarkers Statistical issues 结肠癌 直肠癌 病理 治疗 临床
  • 相关文献

参考文献2

二级参考文献40

  • 1Jie-KaiYu,Yi-DingChen,ShuZheng.An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics[J].World Journal of Gastroenterology,2004,10(21):3127-3131. 被引量:30
  • 2Koike A, Takagi T. Prediction of protein-protein interaction sites using support vector machines. Protein Eng Des Sel 2004;17:165-173.
  • 3Church TR, Yeazel MW, Jones RM, Kochevar LK, Watt GD,Mongin SJ, Cordes JE, Engelhard D. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening. J Natl Cancer Inst 2004; 96:770-780.
  • 4Kornek GV, Depisch D, Rosen HR, Temsch EM, Scheithauer W.Comparative analysis of CA72-4, CA195 and carcinoembryonic antigen in patients with gastrointestinal malignancies. J Cancer Res Clin Oncol 1992; 118:318-320.
  • 5Posner MR, Mayer RJ. The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am 1994; 8:533-553.
  • 6Ohuchi N, Takahashi K, Matoba N, Sato T, Taira Y, Sakai N,Masuda M, Mori S. Comparison of serum assays for TAG-72,CA19-9 and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 1989; 19:242-250.
  • 7Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers. Surg Today 1994; 24:518-525.
  • 8Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A,Yamaguchi H, Yasutake T, Ayabe H, Arisawa K. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Hepatogastroenterology 2003; 50:696-699.
  • 9Srinivas PR, Srivastava S, Hanash S, Wright GL Jr. Proteomics in early detection of cancer. Clin Chem 2001; 47:1901-1912.
  • 10Hurlstone DP, Fujii T, Lobo AJ. Early detection of colorectal cancer using high-magnification chromoscopic colonoscopy.Br J Surg 2002; 89:272-282.

共引文献69

同被引文献20

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部